Skip to content
drillr.ai
Sign up

BIIB

Biogen Inc.

NASDAQ · Healthcare · Drug Manufacturers - General · US

$220.83
−1.64%
Ask drillr

  • Aug 26, 2026, 09:31 UTC

    Japan's Ministry of Health, Labour and Welfare expert panel deliberated on approval of Eisai and Biogen's Alzheimer's drug Leqembi subcutaneous injection formulation, which would allow home administration.

    Source:

  • Aug 25, 2026, 23:35 UTC

    Veeva Systems announced that Biogen has selected Veeva Vault CRM globally.

    Source:

  • Aug 25, 2026, 14:45 UTC

    The Irish Health Service Executive (HSE) approved reimbursement of Biogen's drug Skyclarys for patients with Friedrich's Ataxia, announced on 25 August 2026.

    Source:

  • Aug 6, 2026, 22:15 UTC

    Biogen Inc. completed its acquisition of RayThera Inc., a privately held biotechnology company focused on immunology therapies.

    Source:

  • Aug 1, 2026, 08:21 UTC

    Amundi increased its stake in Biogen Inc. by 38.2% during the first quarter, acquiring an additional 218,398 shares, as disclosed in a recent SEC filing.

    Source:

  • Jul 29, 2026, 10:00 UTC

    Biogen reported second-quarter revenue of $2.74 billion, beating market expectations of $2.47 billion.

    Source:

  • Jul 15, 2026, 15:55 UTC

    Biogen presented detailed phase II study data for its Alzheimer's drug diranersen, reaffirming a setback, and announced plans to advance the drug into phase III trials despite missed goals.

    Source:

  • Jul 14, 2026, 02:23 UTC

    Eisai and Biogen received FDA approval for a subcutaneous injection version of Alzheimer's drug lecanemab (Leqembi) for use in early treatment, with a US launch planned for late August 2026.

    Source:

  • Jun 26, 2026, 13:56 UTC

    Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.

    Source:

  • Jun 17, 2026, 22:59 UTC

    Biogen Inc. agreed to acquire RayThera Inc. for up to $1 billion.

    Source:

  • Jun 5, 2026, 00:00 UTC

    AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.

  • Jun 4, 2026, 11:30 UTC

    Biogen Inc. received FDA Breakthrough Therapy Designation for its drug salanersen for spinal muscular atrophy.

    Source:

  • Jun 3, 2026, 11:30 UTC

    Biogen Inc. announced that fourteen abstracts on its nephrology portfolio, including EMPAVELI and felzartamab, were accepted for presentation at the ERA and ATC congresses.

    Source: